UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Link zum Volltext

Verfügbarkeit prüfen

Autophagy in malignant transformation and cancer progression

The EMBO journal, 2015-04, Vol.34 (7), p.856-880

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of Autophagy in Breast Cancer

Autophagy, 2007-11, Vol.3 (6), p.610-613

2007

Link zum Volltext

Verfügbarkeit prüfen

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Link zum Volltext

Verfügbarkeit prüfen

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Link zum Volltext

Verfügbarkeit prüfen

Autophagy and cancer cell metabolism

Seminars in cell & developmental biology, 2012-06, Vol.23 (4), p.395-401

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Link zum Volltext

Verfügbarkeit prüfen

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

The journal of pathology. Clinical research, 2024-05, Vol.10 (3), p.e12371-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Link zum Volltext

Verfügbarkeit prüfen

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Methods in Enzymology, 2008, Vol.446, p.61-76

2008

Link zum Volltext

Verfügbarkeit prüfen

Role and regulation of autophagy in cancer

Biochimica et biophysica acta, 2009-09, Vol.1793 (9), p.1516-1523

2009

Link zum Volltext

Verfügbarkeit prüfen

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Autophagy, 2014-11, Vol.10 (11), p.2036-2052

2014

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

The Lancet (British edition), 2021-07, Vol.398 (10294), p.24-25

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653

2021

Link zum Volltext

Verfügbarkeit prüfen

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Journal of translational medicine, 2014-03, Vol.12 (1), p.79-79, Article 79

2014

Link zum Volltext

Verfügbarkeit prüfen

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Autophagy, 2014-04, Vol.10 (4), p.662-676

2014

Link zum Volltext

Verfügbarkeit prüfen

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Methods in Enzymology, 2009, Vol.453, p.53-81

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Link zum Volltext

Verfügbarkeit prüfen

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 60

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(60)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Animals
(19)
Humans
(14)
Autophagy
(11)
Mice
(11)
Cell Biology
(10)
Female
(9)
Biochemistry & Molecular Biology
(8)
Breast Cancer
(7)
Apoptosis
(5)
Autophagy - Physiology
(5)
Beclin-1
(5)
Neoplasms - Pathology
(5)
Cancer
(4)
Chemotherapy
(4)
Developmental Biology
(4)
Neoplasms - Metabolism
(4)
Alleles
(3)
Apoptosis Regulatory Proteins - Metabolism
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Early Triple-Negative Breast Cancer

Autophagy in malignant transformation and cancer progression

Role of Autophagy in Breast Cancer

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Autophagy and cancer cell metabolism

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Role and regulation of autophagy in cancer

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Aktive Filter

Suchergebnisse filtern